Detail of "157-03-9"

Reference

6-Diazo-5-oxo-L-norleucine, 2-amino-5-chlorolevulinic acid, and 5-diazo-4-oxo-L-norvaline

6-Diazo-5-oxo-L-norleucine, 2-amino-5-chlorolevulinic acid, and 5-diazo-4-oxo-L-norvaline. I. Inhibition of L-asparagine synthetase in vitro. Jayaram, Hiremagalur N.; Cooney, David A.; Milman, Harry A.; Homan, Elton R.; Rosenbluth, Richard J. (Natl. Cancer Inst., Natl. Inst. Health, Bethesda, Md.There are some reagents with their cas registry numbers 7444-55-5 and 9032-84-2 are used in this study., USA). Biochem. Pharmacol., 25(14), 1571-82 (English) 1976. CODEN: BCPCA6. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 2 6-Diazo-5-oxo-L-norleucine (I) [157-03-9] and 2-amino-5-chlorolevulinic acid (II) [7444-55-5] (1mM) inhibited .apprx.90% of the in vitro utilization of glutamine [56-85-9] by L-asparagine synthetase (EC 6.3.5.4) (III) [37318-72-2] from leukemia 5178Y made resistant to L-asparaginase (EC 3.5.1.1) and from mouse pancreas, whereas 5-diazo-4-oxo-L-norvaline (IV) [17808-06-9] inhibited III by .apprx.50%. Inhibition produced by IV was reversed by dialysis, whereas that produced by I and II was irreversible. Eight fetal rat liver amidotransferases were inhibited strongly by I and II, and 2 were slightly inhibited by IV. IV and I were the best inhibitors of asparagine [70-47-3]- glutamine-utilizing enzymes resp., whereas II affected both groups to a variable degree. I is therefore the most universally active antagonist of glutamine in vitro, followed by II then IV; all 3 can antagonize asparagine under appropriate conditions. .

Ultrastructure of the expected fusion zone in rat fetuses with diazo-oxo-norleucine (DON)-induced cleft palate

Ultrastructure of the expected fusion zone in rat fetuses with diazo-oxo-norleucine (DON)-induced cleft palate. Morgan, P. R.; Pratt, R. M. (Fac. Odontol., Univ. Goeteborg, Goeteborg, Swed.). Teratology, 15(3), 281-9 (English) 1977. CODEN: TJADAB. DOCUMENT TYPE: Journal CA Section: 4 (Toxicology) The aim of this study was to det. whether the glutamine analog 6-diazo-5-oxo-L-norleucine (DON) [157-03-9], which is known to inhibit cell degeneration in rat palatal processes in vitro, exerted a similar effect on cleft palatal processes in vivo. Sprague-Dawley rats were injected intraperitoneally with 5.0 mg/kg of DON on day 15 of gestation and fetuses were removed over days 16, 17 and 18. A high frequency (80-90%) of cleft palate was obtained. Fetal heads were removed on each of the 3 days and transverse sections of the palatal processes were examd. by light and electron microscopy. Treatment with DON failed to inhibit degenerative changes in the palatal epithelium. The same sequence and timing of ultrastructural changes occurred in the expected fusion zone (EFZ) as have been described previously in cleft palatal processes from Meclozine-treated and amniotic sac punctured rat fetuses; namely, autophagic cytoplasmic degeneration, loss of basal lamina and the subepithelial accumulation of macrophages all of which were most prominent in that part of the EFZ immediately next to the developing oral epithelium. The results therefore suggest that a teratogenic dose of DON does not interfere with the ultrastructurally observable changes in the EFZ.